A New Paradigm for NIH Grants

Giving out smaller grants, but for larger periods of time, will fix a system in distress.

Written byNejat Düzgünes
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Making Grants Go Further:
The Perils of Industrialization

The NIH grant funding system is in distress. The success rate for nonamended applications was less than 10% in 2005, 1 with the system overwhelmed by a large number of grant applications that are impossible to distinguish in terms of their significance and merit. Multiple resubmissions are common.

Although the NIH has introduced a new structure for review committees and some pilot changes, success rates have not improved. This crisis cannot be solved by tinkering with peer review, whose many problems I delineated in these pages eight years ago. 2 At the time, the NIH stated that it was seriously addressing these issues by emphasizing innovation, expediting the funding of recently reviewed grants, and improving study sections in its "Boundaries" process. Such minor changes have not improved the funding of biomedical research, and I therefore challenge the NIH to completely shift its ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies